A novel approach for characterization of KSHV-associated multicentric Castleman disease from effusions.

KSHV inflammatory cytokine syndrome KSHV-MCD flow cytometry lambda-restricted plasmablasts

Journal

British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544

Informations de publication

Date de publication:
02 2023
Historique:
revised: 03 10 2022
received: 16 06 2022
accepted: 05 10 2022
pubmed: 21 10 2022
medline: 7 2 2023
entrez: 20 10 2022
Statut: ppublish

Résumé

A biopsy of lymphoid tissue is currently required to diagnose Kaposi sarcoma-associated herpesvirus (KSHV)-associated multicentric Castleman disease (KSHV-MCD). Patients showing clinical manifestations of KSHV-MCD but no pathological changes of KSHV-MCD are diagnosed as KSHV inflammatory cytokine syndrome. However, a lymph node biopsy is not always feasible to make the distinction. A pathognomonic feature of lymph nodes in KSHV-MCD is the expansion of KSHV-infected, lambda-restricted but polyclonal plasmablasts. To investigate whether these cells also reside in extra-nodal sites, effusion from 11 patients with KSHV-MCD and 19 with KSHV inflammatory cytokine syndrome was analysed by multiparametric flow cytometry. A distinct, lambda-restricted plasmablastic population (LRP) with highly consistent immunophenotype was detected in effusions in 8/11 patients with KSHV-MCD. The same population was also observed in 7/19 patients with KSHV inflammatory cytokine syndrome. The detection of LRP stratified KSHV inflammatory cytokine syndrome into two clinically distinct subgroups; those with detectable LRP closely resembled KSHV-MCD, showing similar KSHV viral load, comparable severity of thrombocytopenia and hypoalbuminaemia, and similar incidences of hepatosplenomegaly. Collectively, the detection of LRP by flow cytometry can serve as a valuable tool in diagnosing KSHV-MCD. KSHV inflammatory cytokine syndrome with LRP in effusions may represent a liquid-form of KSHV-MCD.

Identifiants

pubmed: 36264007
doi: 10.1111/bjh.18518
pmc: PMC10165722
mid: NIHMS1847480
doi:

Substances chimiques

Cytokines 0

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

462-475

Subventions

Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201500003I
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Published 2022. This article is a U.S. Government work and is in the public domain in the USA.

Références

Pathologica. 2021 Oct;113(5):339-353
pubmed: 34837092
Blood. 2000 Feb 15;95(4):1406-12
pubmed: 10666218
AIDS. 2021 Jan 1;35(1):53-62
pubmed: 33273183
Blood. 1995 Aug 15;86(4):1276-80
pubmed: 7632932
J Virol Methods. 2001 Feb;91(2):109-17
pubmed: 11164492
Blood Adv. 2021 Mar 23;5(6):1660-1670
pubmed: 33720337
Front Microbiol. 2012 Mar 02;3:73
pubmed: 22403576
Blood. 2001 Apr 1;97(7):2130-6
pubmed: 11264181
Blood. 2018 Nov 29;132(22):2323-2330
pubmed: 30487129
Clin Infect Dis. 2016 Mar 15;62(6):730-738
pubmed: 26658701
Clin Infect Dis. 2010 Aug 1;51(3):350-8
pubmed: 20583924
J Clin Pathol. 2007 May;60(5):524-8
pubmed: 16816169
Mod Pathol. 2017 May;30(5):745-760
pubmed: 28084335
Eur J Haematol. 2013 Dec;91(6):497-503
pubmed: 23992152
Hematol Oncol Clin North Am. 2018 Feb;32(1):75-88
pubmed: 29157621
J Virol. 1999 May;73(5):4181-7
pubmed: 10196314
Clin Infect Dis. 2008 Sep 1;47(5):684-8
pubmed: 18652555
Haematologica. 2002 Apr;87(4):339-43
pubmed: 11940475
Histopathology. 2008 Nov;53(5):513-24
pubmed: 18983461
Curr Opin Pulm Med. 2001 Jul;7(4):202-9
pubmed: 11470975
Semin Diagn Pathol. 2016 Sep;33(5):294-306
pubmed: 27296355
Science. 1994 Dec 16;266(5192):1865-9
pubmed: 7997879

Auteurs

Ting Zhou (T)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Constance M Yuan (CM)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Kathryn Lurain (K)

HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Clarissa Rous (C)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Linda Weaver (L)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Mark Raffeld (M)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Maryalice Stetler-Stevenson (M)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Thomas S Uldrick (TS)

HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Armando C Filie (AC)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Stefania Pittaluga (S)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Elaine S Jaffe (ES)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Vickie Marshall (V)

Viral Oncology Section, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

Kyle Moore (K)

Viral Oncology Section, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

Denise Whitby (D)

Viral Oncology Section, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

Ramya Ramaswami (R)

HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Robert Yarchoan (R)

HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Hao-Wei Wang (HW)

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH